



## Short Communication

## Inhibition of primary clinical isolates of human parainfluenza virus by DAS181 in cell culture and in a cotton rat model

B.G. Jones<sup>a</sup>, R.T. Hayden<sup>b</sup>, J.L. Hurwitz<sup>a,c,\*</sup><sup>a</sup> Department of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA<sup>b</sup> Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA<sup>c</sup> Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, 858 Madison Avenue, Memphis, TN 38163, USA

## ARTICLE INFO

## Article history:

Received 12 June 2013

Revised 12 September 2013

Accepted 15 September 2013

Available online 27 September 2013

## Keywords:

Parainfluenza viruses

DAS181 virus inhibitor

Cotton rats

In vitro

In vivo

## ABSTRACT

DAS181 is a novel drug in development for the treatment of influenza as well as human parainfluenza viruses (hPIVs). Previous studies demonstrated that DAS181 inhibited laboratory strains of hPIV, but no tests were conducted with primary clinical isolates of hPIV. To fill this gap, we studied six primary isolates including hPIV-2 and hPIV-3. First tests showed that the amplification of all viruses *in vitro* was reproducibly inhibited with DAS181 drug concentrations ranging between 0.1 and 1 nM. An hPIV-3 primary clinical isolate was then tested in a cotton rat model for sensitivity to 0.3–1 mg/kg drug treatments. Results showed that virus amplification in the lower respiratory tract was significantly and reproducibly inhibited by drug. Together, experiments demonstrated that DAS181 inhibited primary clinical isolates of hPIV *in vitro* and *in vivo* at doses similar to those previously described for inhibition of laboratory hPIV and influenza virus isolates.

© 2013 Elsevier B.V. All rights reserved.

Human parainfluenza viruses (hPIVs) belong to the paramyxovirus family and include subtypes 1–4. These subtypes cause diseases of different severity ranging from common cold symptoms to serious laryngotracheobronchitis (croup) or bronchiolitis. Human PIV-1 infections cause at least 50% of croup cases in the United States with an estimated 18,000–35,000 children younger than 5 years hospitalized each year (Henrickson, 2003). Hospitalizations with hPIV-3 infections are even more frequent and tend to associate with lower respiratory tract disease including bronchiolitis and pneumonia (Weinberg et al., 2009). Human PIV-2 and hPIV-4 associate with fewer respiratory tract infections, but like the others, can cause serious disease in immunocompromised hosts (Boeckh, 2008; Falsey, 2012; Hall, 2001; Karron & Collins, 2007; Renaud and Englund, 2012; Weigt et al., 2011).

Currently, no standard prophylaxis or therapy exists for prevention or treatment of hPIV. Several vaccines have been tested, but none have yet reached licensure (Hurwitz et al., 1997; Jones et al., 2009, 2012; Karron et al., 2012; Karron & Collins, 2007; Skiadopoulos et al., 1999; Slobod et al., 2004). Ribavarin is used in some cases as treatment against hPIV in immunocompromised patients, but the results have been variable (Fuehner et al., 2011; Riner et al., 2009; Ustun et al., 2012), and candidate drugs such

as BCX 2798 and BCX 2855 have not yet advanced to clinical testing (Alymova et al., 2004; Watanabe et al., 2009). The development of better treatment options for the hPIVs is therefore encouraged.

The host cell receptors for hPIVs are cell surface sialic acids (Ito, 2000). These are  $\alpha$ -keto acids with 9-carbon backbones, usually found at the outermost positions of oligosaccharide chains attached to glycoproteins and glycolipids. The predominant type of sialic acid is N-acetylneuraminic acid (Neu5Ac), which is the biosynthetic precursor for most other types. Two major linkages between Neu5Ac and galactose residues of carbohydrate side chains are found in nature, Neu5Ac  $\alpha$ (2,3)–Gal ( $\alpha$ 2,3-linked sialic acids) and Neu5Ac  $\alpha$ (2,6)–Gal ( $\alpha$ 2,6-linked sialic acids). The hemagglutinin-neuraminidase (HN) molecules of hPIVs 1–4 recognize  $\alpha$ (2,3)-linked sialic acids, while hPIV-3 is also known to recognize  $\alpha$ (2,6)-linkages (Schauer, 1982; Suzuki et al., 2001). In some cases a second receptor site is exposed on the HN of hPIV-1 or hPIV-3 that may broaden receptor recognition (Alymova et al., 2012; Mishin et al., 2010). In the cotton rat, often used as an animal model for hPIV infections,  $\alpha$ (2,3)-linked sialic acid is present in the trachea and both  $\alpha$ (2,3)- and  $\alpha$ (2,6)-linked sialic acids are present in the lung (Blanco et al., 2013).


Sialidases are a family of exoglycosidases that catalyze the removal of terminal sialic acid residues from various glycoconjugates, and that can inhibit influenza viruses and hPIVs *in vitro* (Ah-Tye et al., 1999; Air and Laver, 1995; Bergelson et al., 1982; Els et al., 1989; Griffin et al., 1983; Moscona and Peluso, 1991, 1992; Suzuki et al., 2001; Zhang et al., 2005). DAS181 is a protein

\* Corresponding author at: Department of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA. Tel.: +1 901 595 2464; fax: +1 901 595 3099.


E-mail addresses: [bart.jones@stjude.org](mailto:bart.jones@stjude.org) (B.G. Jones), [randall.hayden@stjude.org](mailto:randall.hayden@stjude.org) (R.T. Hayden), [julia.hurwitz@stjude.org](mailto:julia.hurwitz@stjude.org) (J.L. Hurwitz).

DAS181 was previously tested on laboratory isolates (Moscona et al., 2010). Because the laboratory isolates may have been selected for unique characteristics atypical of the clinical setting, we questioned whether a panel of primary virus isolates that had undergone limited passages would also be sensitive to drug. To this end, we collected six primary virus isolates (two hPIV-2 and four hPIV-3 isolates) from St. Jude Children's Research Hospital. Viruses

To determine if DAS181 inhibited hPIV isolates *in vitro*, virus was added to confluent LLC-MK2 cell cultures and incubated for 2 h, after which plates were washed and replaced with media containing varying concentrations of DAS181. Plates were incubated for 4–5 additional days and then scored by hemagglutination (HA) assays. As demonstrated in Fig. 2, all clinical isolates were completely inhibited following incubation with 0.1–1 nM DAS181. Studies with hPIV-1 were also conducted, but required



**Fig. 1.** hPIV-2 and hPIV-3 protein sequences. Sanger sequencing was conducted to identify HN sequences for each primary virus isolate. Predicted amino acid sequences are aligned to the templates of Greer for hPIV-2 (1A) and C243 for hPIV-3 (1B). A blank position indicates lack of sequence information. A dot indicates a match with the template, and a single-letter code indicates an amino acid substitution. Methods: viral RNA was purified using a Qiagen QIAmp Viral RNA Mini Kit (Cat# 52904) and RT-PCR was conducted with virus sequence-specific primers (synthesized by Integrated DNA Technologies) and a RNA One-step PCR Kit from TaKaRa Bio, Inc. (Cat# RR024). Sanger sequencing was then performed at the Hartwell Center of St. Jude Children's Research Hospital using additional virus sequence-specific primers. For analyses, individual sequences were imported into DNA Lasergene 7 SeqMan software and aligned to create a consensus contig. Contigs were translated and aligned using CLC Main Workbench 5 software.



**Fig. 2.** DAS181 inhibited amplification of hPIV primary isolates *in vitro*. Serially diluted DAS181 was tested for inhibition of hPIV-2 and hPIV-3 amplification *in vitro*. Methods: To test sensitivity of viruses to DAS181, LLC-MK2 cells were plated in 96-well tissue culture plates and grown to confluency in MEM, 0.225% NaHCO<sub>3</sub>, 5% Fetal Bovine Serum, L-glutamine and gentamicin at 37 °C, 5% CO<sub>2</sub>. Viruses were diluted in DMEM, 0.1% BSA, L-glutamine, gentamicin to a concentration of 250 TCID<sub>50</sub> per 100 µl. LLC-MK2 plates were washed with DPBS w/Mg<sup>++</sup> and Ca<sup>++</sup> and 100 µl/well of the diluted virus were added and incubated for 2 h at 37 °C. After incubation, plates were aspirated, washed with DPBS, followed by addition of 100 µl DAS181 serially diluted from 1 to 0.001 nM in DMEM, 0.1% Bovine Serum Albumin. Twelve well replicates were performed for each virus and each drug dilution. Cultures were incubated for 4–5 days at 37 °C after which wells were scored for hemagglutination (HA) activity. HA assays were conducted at 4 °C using turkey red blood cells (RBCs) for hPIV-3 isolates and guinea pig RBCs for hPIV-2 isolates. Percent inhibition was scored based on reduction in the number of HA-positive wells in the presence of drug. Control HA assays were set up with DAS181 and serially diluted hPIV-2 or hPIV-3 stocks, demonstrating that HA assays were not inhibited by the addition of 0–1 nM drug at 4 °C.

5 µg/ml acetylated trypsin for extracellular cleavage of the hPIV-1 fusion protein (Karron & Collins, 2007). Full virus inhibition was observed with DAS181, but higher drug concentrations were required for inhibition of hPIV-1 as compared to hPIV-2 and hPIV-3. The explanation for this result was unclear, although it is likely that the input of trypsin at high concentration digested and partially inactivated drug (data not shown).

Evidence that clinical hPIV isolates could be inhibited *in vitro* prompted *in vivo* studies. After a test of viral isolates hPIV-2 8/2/

00, hPIV-2 1/1/97 and hPIV-3#14 for amplification in cotton rats, the isolate that yielded the highest titer on days 3–4 after infection (hPIV-3#8) was selected for further study. In a preliminary experiment, animals were infected with  $\sim 1.5 \times 10^6$  TCID<sub>50</sub> hPIV-3#8 followed 4 h later with drug (0.3–1 mg/kg by the i.n. route, a concentration that was selected based on previous studies (Moscona et al., 2010). Repeat drug doses were on days 1 and 2 and viral measurements were conducted on day 3. As shown in Fig. 3A, there was a significant decrease in virus amplification. The next experiments assessed the antiviral activity when 1 mg/kg drug was administered 1 h before virus infection rather than 4 h after infection. As shown in Fig. 3B, DAS181-treated animals again showed significant reduction of virus, in this case with inhibition of virus approaching two logs. To determine whether the antiviral effects of DAS181 were more evident in the upper or lower respiratory tract tissues (URT or LRT), experiments were next conducted to assess nasal turbinates and lungs in parallel. Results revealed that the reduction of hPIV-3 by DAS181 treatments was not statistically significant in the nasal turbinates, but was reproducibly inhibitory in the lung (Fig. 3C).


Of note, we have not asked if drug can be initiated 1 or 2 days after viral infection in cotton rats, although clinical studies are addressing this question. We note that the protection afforded by drug administered prior to infection appeared to be best. This is consistent with previous literature, suggesting that prophylaxes associate with the best protective effects against paramyxoviruses (Groothuis et al., 2011).

Taken together, data add to our understanding of DAS181-mediated inhibition of the hPIVs. All hPIV-2 and hPIV-3 isolates were susceptible to full inhibition by DAS181 *in vitro* with drug doses of 0.1–1 nM. Of interest, this drug range was comparable to that described previously for inhibition of influenza viruses and laboratory strains of hPIV (Ah-Tye et al., 1999; Moscona et al., 2010). Our cotton rat model further illustrated that hPIV-3 could be inhibited by DAS181 *in vivo*, more so in the lung than in the nasal turbinates. Differences in locations might have been a simple consequence of drug distribution, as a relatively large volume of drug applied to sedated animals readily enters the lung (Burke et al., 2011). In addition, the differing distributions of epithelial cells and sialic acid moieties throughout the respiratory tract (Rackley and Stripp, 2012) may have influenced drug efficacy. The reduction of hPIV-3 amplification in lung tissue by DAS181 is a highly desirable attribute, given that the morbidity and mortality caused by hPIV-3 is predominantly due to LRT infections. URT infections with hPIV-3 are generally mild, and the short-term deposition of viral antigen has the potential to promote durable B and T cell residence in nasal associated lymphoid tissues (Rudraraju et al., 2011) to protect individuals from disease upon future virus exposure. Of note, DAS181 may be formulated in variable particle sizes to direct drug deposition either to URT or LRT tissues as desired.

DAS181 has recently been used to treat four severely ill immunocompromised patients who became infected with hPIV. Cases included stem cell and lung transplant patients, all of whom experienced an improved clinical outcome after treatment and two of whom experienced a reduced viral load (Chen et al., 2011; Drozd et al., 2013; Guzman-Suarez et al., 2012). Given that there is no licensed hPIV vaccine and that hPIV-infected patients are usually treated only with supportive care, DAS181 may provide an important new drug option for a currently unmet medical need in both adult and pediatric healthcare arenas.

## Acknowledgments

This work was supported in part by NIH, NIAID Grants P01-AI-054955, R01-AI088729 and R01-AI78819, NCI Grant P30-CA21765 and the American Lebanese Syrian Associated Charities (ALSAC).



**Fig. 3.** DAS181 inhibits LRT hPIV-3 amplification *in vivo* in a cotton rat model. (A) In the cotton rat model, DAS181 was tested for inhibition of hPIV-3#8 amplification. Briefly, cotton rats (Harlan, Inc., Indianapolis Indiana) were infected with  $\sim 1.5 \times 10^6$  TCID<sub>50</sub> HPIV-3 in 100  $\mu$ l i.n. 4 h later, test animals were given a dose of DPBS or DAS181 at 0.3 or 1.0 mg/kg body weight in a volume of 100  $\mu$ l by the i.n. route. Two more doses of drug were given 1 and 2 days after infection. On day 3 following infection, lungs were harvested and homogenized in 3–5 ml DPBS. For titrating, samples were serially diluted from  $10^{-1}$  through  $10^{-6}$  and 200  $\mu$ l/well were inoculated onto LLC-MK2 monolayers in replicate wells of 96-well plates. Plates were incubated at 33 °C in 5% CO<sub>2</sub> for 4 days. 50  $\mu$ l supernatant from each well was removed, mixed with 50  $\mu$ l turkey RBC, and incubated at 4 °C for 45 min to 1 h. Wells were scored as positive or negative for hemagglutination (HA). Virus titers (TCID<sub>50</sub>) were calculated based on HA data for each test animal using the Reed–Meunch formula. Each symbol represents the result from an individual animal. For DAS-181-treated animals, semi-solid and solid dots represent animals that received 0.3 or 1 mg/kg drug, respectively. (B) Experiments were conducted as in (A), but the first dose of drug was administered 1 h prior to infection rather than 4 h after infection. (C) Experiments were conducted as in (B), but with measurements of viral titers in nasal turbinates as well as lungs. To harvest nasal turbinates soft tissues were removed from bony structures, suspended in 1 ml DPBS, and screened through a 70  $\mu$  filter.

We thank Drs. Allen Portner and Irina Alymova of St. Jude for constructive advice. We thank the St. Jude Hartwell Center for conducting Sanger sequencing. We thank Drs. R.L. Routh and R.B. Moss of Ansun Biopharma, San Diego, CA for provision of drug, for advice concerning experimental design and for assistance with data interpretation and manuscript preparation.

## References

- Ah-Tye, C., Schwartz, S., Huberman, K., Carlin, E., Moscona, A., 1999. Virus-receptor interactions of human parainfluenza viruses types 1, 2 and 3. *Microb. Pathogen.* 27, 329–336.
- Air, G.M., Laver, W.G., 1995. Red cells bound to influenza virus N9 neuraminidase are not released by the N9 neuraminidase activity. *Virology* 211, 278–284.
- Alymova, I.V., Taylor, G., Takimoto, T., Lin, T.H., Chand, P., Babu, Y.S., Li, C., Xiong, X., Portner, A., 2004. Efficacy of novel hemagglutinin–neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses *in vitro* and *in vivo*. *Antimicrob. Agents Chemother.* 48, 1495–1502.
- Alymova, I.V., Portner, A., Mishin, V.P., McCullers, J.A., Freiden, P., Taylor, G.L., 2012. Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin–neuraminidase glycoprotein. *Glycobiology* 22, 174–180.
- Bergelson, L.D., Bukrinskaya, A.G., Prokavova, N.V., Shaposhnikova, G.I., Kocharov, S.L., Shevchenko, V.P., Kornilava, G.V., Fomina-Ageeva, E.V., 1982. Role of gangliosides in reception of influenza virus. *Eur. J. Biochem.* 128, 467–474.
- Blanco, J.C., Pletneva, L.M., Wan, H., Araya, Y., Angel, M., Oue, R.O., Sutton, T.C., Perez, D.R., 2013. Receptor characterization and susceptibility of cotton rats to avian and 2009 pandemic influenza virus strains. *J. Virol.* 87, 2036–2045.
- Boeckh, M., 2008. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. *Br. J. Haematol.* 143, 455–467.
- Burke, C.W., Mason, J.N., Surman, S.L., Jones, B.G., Dalloneau, E., Hurwitz, J.L., Russell, C.J., 2011. Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy. *PLoS Pathog.* 7, e1002134.
- Chen, Y.B., Driscoll, J.P., McAfee, S.L., Spitzer, T.R., Rosenberg, E.S., Sanders, R., Moss, R.B., Fang, F., Marty, F.M., 2011. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. *Clin. Infect. Dis.* 53, e77–e80.
- Droz, D.R., Limaye, A.P., Moss, R.B., Sanders, R.L., Hansen, C., Edelman, J.D., Raghu, G., Boeckh, M., Rakita, R.M., 2013. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. *Transpl. Infect. Dis.* 15, E28–E32.
- Els, M.C., Laver, W.G., Air, G.M., 1989. Sialic acid is cleaved from glycoconjugates at the cell surface when influenza virus neuraminidases are expressed from recombinant vaccinia viruses. *Virology* 170, 346–351.
- Falsey, A.R., 2012. Current management of parainfluenza pneumonitis in immunocompromised patients: a review. *Infect. Drug Resist.* 5, 121–127.
- Fuehner, T., Dierich, M., Duesberg, C., DeWall, C., Welte, T., Haverich, A., Warnecke, G., Simon, A.R., Gottlieb, J., 2011. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. *Antivir. Ther.* 16, 733–740.
- Griffin, J.A., Basak, S., Compans, R.W., 1983. Effects of hexose starvation and the role of sialic acid in influenza virus release. *Virology* 125, 324–334.
- Groothuis, J.R., Hoopes, J.M., Hemming, V.G., 2011. Prevention of serious respiratory syncytial virus-related illness. II: immunoprophylaxis. *Adv. Ther.* 28, 110–125.
- Guzman-Suarez, B.B., Buckley, M.W., Gilmore, E.T., et al., 2012. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. *Transpl. Infect. Dis.* 14, 427–433.
- Hall, C.B., 2001. Respiratory syncytial virus and parainfluenza virus. *N. Engl. J. Med.* 344, 1917–1928.
- Henrickson, K.J., 2003. Parainfluenza viruses. *Clin. Microbiol. Rev.* 16, 242–264.
- Hurwitz, J.L., Soike, K.F., Sangster, M.Y., Portner, A., Sealy, R.E., Dawson, D.H., Coleclough, C., 1997. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. *Vaccine* 15, 533–540.
- Ito, T., 2000. Interspecies transmission and receptor recognition of influenza A viruses. *Microbiol. Immunol.* 44, 423–430.
- Jones, B., Zhan, X., Mishin, V., Slobod, K.S., Surman, S., Russell, C.J., Portner, A., Hurwitz, J.L., 2009. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-3 and RSV. *Vaccine* 27, 1848–1857.
- Jones, B.G., Sealy, R.E., Rudraraju, R., Traina-Dorge, V.L., Finneyfrock, B., Cook, A., Takimoto, T., Portner, A., Hurwitz, J.L., 2012. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. *Vaccine* 30, 959–968.
- Karron, R.A., Collins, P.L., 2007. Parainfluenza viruses. In: Knipe, D.M., Howley, P.M., Griffin, D.E., Lamb, R.A., Martin, M.A., Roizman, B., Straus, E. (Eds.), *Fields Virology*. Lippincott Williams and Wilkins, pp. 1497–1526.
- Karron, R.A., Thumar, B., Schappell, E., Surman, S., Murphy, B.R., Collins, P.L., Schmidt, A.C., 2012. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. *Vaccine* 30, 3975–3981.
- Mishin, V.P., Watanabe, M., Taylor, G., DeVincenzo, J., Bose, M., Portner, A., Alymova, I.V., 2010. N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin–neuraminidase masks a second receptor-binding site. *J. Virol.* 84, 3094–3100.
- Moscona, A., Peluso, R.W., 1991. Fusion properties of cells persistently infected with human parainfluenza virus type 3: participation of hemagglutinin–neuraminidase in membrane fusion. *J. Virol.* 65, 2773–2777.
- Moscona, A., Peluso, R.W., 1992. Fusion properties of cells infected with human parainfluenza virus type 3: receptor requirements for viral spread and virus-mediated membrane fusion. *J. Virol.* 66, 6280–6287.
- Moscona, A., Porotto, M., Palmer, S., et al., 2010. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection *in vitro* and *in vivo*. *J. Infect. Dis.* 202, 234–241.
- Moss, R.B., Hansen, C., Sanders, R.L., Hawley, S., Li, T., Steigbigel, R.T., 2012. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. *J. Infect. Dis.* 206, 1844–1851.
- Rackley, C.R., Stripp, B.R., 2012. Building and maintaining the epithelium of the lung. *J. Clin. Invest.* 122, 2724–2730.
- Renaud, C., Englund, J.A., 2012. Antiviral therapy of respiratory viruses in haematopoietic stem cell transplant recipients. *Antivir. Ther.* 17, 175–191.
- Riner, A., Chan-Track, K.M., Murray, J., 2009. Intravenous ribavirin-review of the FDA's emergency investigational new drug database (1997–2008) and literature review. *Postgrad. Med.* 121, 139–146.
- Rudraraju, R., Surman, S., Jones, B., Sealy, R., Woodland, D.L., Hurwitz, J.L., 2011. Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut. *Virology* 410, 429–436.
- Schauer, R., 1982. Chemistry, metabolism and biological functions of sialic acids. *Adv. Carbohydr. Chem. Biochem.* 40, 131–234.
- Skidopoulos, M.H., Tao, T., Surman, S.R., Collins, P.L., Murphy, B.R., 1999. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the

- HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. *Vaccine* 18, 503–510.
- Slobod, K.S., Shenep, J.L., Lujan-Zilbermann, J., Allison, K., Brown, B., Scroggs, R.A., Portner, A., Coleclough, C., Hurwitz, J.L., 2004. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. *Vaccine* 22, 3182–3186.
- Suzuki, T., Portner, A., Scroggs, R.A., Uchikawa, M., Koyama, N., Matsuo, K., Suzuki, Y., Takimoto, T., 2001. Receptor specificities of human respiroviruses. *J. Virol.* 75, 4604–4613.
- Ustun, C., Slaby, J., Shanley, R.M., Vydra, J., Smith, A.R., Wagner, J.E., Weisdorf, D.F., Young, J.A., 2012. Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality and changes over time. *Biol. Blood marrow Transplant.* 18, 1580–1588.
- Watanabe, M., Mishin, V.P., Brown, S.A., et al., 2009. Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice. *Antimicrob. Agents Chemother.* 53, 3942–3951.
- Weigt, S.S., Gregson, A.L., Deng, J.C., Lynch 3, J.P., Belperio, J.A., 2011. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. *Semin. Respir. Crit. Care Med.* 32, 471–493.
- Weinberg, G.A., Hall, C.B., Iwane, M.K., et al., 2009. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. *J. Pediatr.* 154, 694–699.
- Zhang, L., Bukreyev, A., Thompson, C.I., Watson, B., Peeples, M.E., Collins, P.L., Pickles, R.J., 2005. Infection of ciliated cells by human parainfluenza virus type 3 in an *in vitro* model of human airway epithelium. *J. Virol.* 79, 1113–1124.